170 related articles for article (PubMed ID: 12869630)
1. Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.
Schenk PW; Brok M; Boersma AW; Brandsma JA; Den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
Mol Pharmacol; 2003 Aug; 64(2):259-68. PubMed ID: 12869630
[TBL] [Abstract][Full Text] [Related]
2. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype.
Schenk PW; Boersma AW; Brok M; Burger H; Stoter G; Nooter K
Mol Pharmacol; 2002 Mar; 61(3):659-66. PubMed ID: 11854447
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
5. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants.
Abe H; Wada M; Kohno K; Kuwano M
Anticancer Res; 1994; 14(5A):1807-10. PubMed ID: 7531413
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae.
Huang RY; Eddy M; Vujcic M; Kowalski D
Cancer Res; 2005 Jul; 65(13):5890-7. PubMed ID: 15994967
[TBL] [Abstract][Full Text] [Related]
8. A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.
Burger H; Capello A; Schenk PW; Stoter G; Brouwer J; Nooter K
Biochem Biophys Res Commun; 2000 Mar; 269(3):767-74. PubMed ID: 10720490
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.
Tirrò E; Consoli ML; Massimino M; Manzella L; Frasca F; Sciacca L; Vicari L; Stassi G; Messina L; Messina A; Vigneri P
Cancer Res; 2006 Apr; 66(8):4263-72. PubMed ID: 16618750
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin sensitivity in cAMP-dependent protein kinase mutants of Saccharomyces cerevisiae.
Cvijic ME; Yang WL; Chin KV
Anticancer Res; 1998; 18(5A):3187-92. PubMed ID: 9858882
[TBL] [Abstract][Full Text] [Related]
11. The yeast multidrug transporter Qdr3 (Ybr043c): localization and role as a determinant of resistance to quinidine, barban, cisplatin, and bleomycin.
Tenreiro S; Vargas RC; Teixeira MC; Magnani C; Sá-Correia I
Biochem Biophys Res Commun; 2005 Feb; 327(3):952-9. PubMed ID: 15649438
[TBL] [Abstract][Full Text] [Related]
12. 1,4-Bis(1-naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance.
Novi M; Ottone M; Dell'Erba C; Barbieri F; Chiavarina B; Maccagno M; Viale M
Oncol Rep; 2004 Jul; 12(1):91-6. PubMed ID: 15201965
[TBL] [Abstract][Full Text] [Related]
13. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
14. A novel role for Bsd2 in the resistance of yeast to adriamycin.
Takahashi T; Furuchi T; Naganuma A
J Cell Physiol; 2005 Jan; 202(1):100-4. PubMed ID: 15389553
[TBL] [Abstract][Full Text] [Related]
15. Ultrastructural changes in tumor cells treated with liposomal forms of anticancer drugs.
Yurchenko OV; Rusetskya NV; Naleskina LA; Chekhun VF
Exp Oncol; 2010 Mar; 32(1):23-8. PubMed ID: 20332761
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
19. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells.
Suzuki H; Hotta T; Koyama T; Komagata M; Imakiire A; Yanase N; Yoshimoto T; Mizuguchi J
Anticancer Res; 2003; 23(4):3247-53. PubMed ID: 12926060
[TBL] [Abstract][Full Text] [Related]
20. Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance.
Kang HC; Kim IJ; Park HW; Jang SG; Ahn SA; Yoon SN; Chang HJ; Yoo BC; Park JG
Cancer Lett; 2007 Mar; 247(1):40-7. PubMed ID: 16644108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
